Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H19NO3S |
| Molecular Weight | 353.435 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C\C=C(/C1=CSC=C1)C2=CC=C(C=C2)C3=CC=CO3)CC(O)=O
InChI
InChIKey=CLNBFFJOAIHNHT-LSCVHKIXSA-N
InChI=1S/C20H19NO3S/c1-21(13-20(22)23)10-8-18(17-9-12-25-14-17)15-4-6-16(7-5-15)19-3-2-11-24-19/h2-9,11-12,14H,10,13H2,1H3,(H,22,23)/b18-8-
| Molecular Formula | C20H19NO3S |
| Molecular Weight | 353.435 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 17:18:01 GMT 2025
by
admin
on
Tue Apr 01 17:18:01 GMT 2025
|
| Record UNII |
25J4W8YK6M
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
452296-40-1
Created by
admin on Tue Apr 01 17:18:01 GMT 2025 , Edited by admin on Tue Apr 01 17:18:01 GMT 2025
|
PRIMARY | |||
|
300000051524
Created by
admin on Tue Apr 01 17:18:01 GMT 2025 , Edited by admin on Tue Apr 01 17:18:01 GMT 2025
|
PRIMARY | |||
|
10269496
Created by
admin on Tue Apr 01 17:18:01 GMT 2025 , Edited by admin on Tue Apr 01 17:18:01 GMT 2025
|
PRIMARY | |||
|
25J4W8YK6M
Created by
admin on Tue Apr 01 17:18:01 GMT 2025 , Edited by admin on Tue Apr 01 17:18:01 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Very recently, Liem-Moolenaar et al. (106) reported the effects of the GlyT-1 inhibitor R 231857 (Fig. 13) on the CNS and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects. R231857 had some small effects on scopolamine-induced CNS-impairment, which were also not clearly dependent on dose. R231857 lacked consistent dose-related effects in this study, probably because the CNS concentrations were too low to produce significant/reproducible CNS effects or to affect the scopolamine challenge in healthy volunteers.
|
||
|
ACTIVE MOIETY |
Very recently, Liem-Moolenaar et al. (106) reported the effects of the GlyT-1 inhibitor R 231857 (Fig. 13) on the CNS and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects. R231857 had some small effects on scopolamine-induced CNS-impairment, which were also not clearly dependent on dose. R231857 lacked consistent dose-related effects in this study, probably because the CNS concentrations were too low to produce significant/reproducible CNS effects or to affect the scopolamine challenge in healthy volunteers.
|
